Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Insight Molecular Diagnostics Inc. (IMDX) had Return on Tangible Equity of 14.80% for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$0.56M |
|
$-3.58M |
|
$0.14M |
|
$0.42M |
|
$4.24M |
|
$-3.68M |
|
$0.10M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.68M |
|
$-3.03M |
|
36.86M |
|
36.86M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$13.88M |
|
$5.55M |
|
$7.86M |
|
$21.74M |
|
$9.51M |
|
$0.50M |
|
$36.41M |
|
$45.92M |
|
$-24.18M |
|
$-24.18M |
|
$-24.18M |
|
32.76M |
|
| Cash Flow Statement Financials | |
$-23.34M |
|
$-2.23M |
|
$24.50M |
|
$12.92M |
|
$11.81M |
|
$-1.10M |
|
$2.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.46 |
|
-- |
|
-- |
|
-0.02 |
|
-0.02 |
|
75.13% |
|
-657.60% |
|
-657.60% |
|
-- |
|
-640.25% |
|
-640.25% |
|
$-25.57M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
0.37 |
|
1.07 |
|
83.72 |
|
14.80% |
|
|
Return on Tangible Equity |
14.80% |
-16.46% |
|
15.11% |
|
$-0.74 |
|
$-0.69 |
|
$-0.63 |
|